Hepion Pharmaceuticals, Inc. (HEPA)
After hours:
Chart Events
Performance Outlook
| Previous Close | 0.7282 |
| Open | 0.7500 |
| Bid | 0.7001 x 1000 |
| Ask | 0.7500 x 3000 |
| Day's Range | 0.7200 - 0.7800 |
| 52 Week Range | 0.6100 - 2.3180 |
| Volume | |
| Avg. Volume | 303,701 |
| Market Cap | 56.849M |
| Beta (5Y Monthly) | 1.35 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.5040 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 4.75 |
- GlobeNewswire
Hepion Pharmaceuticals Announces Clinical Collaboration with HepQuant in Phase 2b NASH Trial
- HepQuant Evaluation Offers Sensitive Measurement of Hepatic Function and Correlation with Clinical Outcomes - - Dedicated Phase 2b Trial Supports Overarching NASH Program for Rencofilstat - - Four-Month, Three Arm Trial will Inform on Numerous NASH Functional Biomarkers - EDISON, N.J., May 03, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treat
- GlobeNewswire
Hepion Pharmaceuticals to Present at the Q1 Investor Summit Conference
EDISON, N.J., March 07, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular carcinoma (“HCC”), announced today that its CMO, Dr. Todd Hobbs, will present at the Q1 Investor Summit Conference on Wednesday, March 9, 2022 at 1:15 p.m. Eastern Time. The virtual presentation will be broa
- GlobeNewswire
Hepion Pharmaceuticals Appoints World-Renowned Hepatologist, Dr. Eddie C. Cheung, to Lead the Company’s Strategic Medical Affairs in Asia
- Dr. Cheung, who has dedicated his career to NASH, hepatocellular carcinoma, fatty liver disease, and viral hepatitis will endeavor to advance Hepion’s business development and partnering efforts in Asia - EDISON, N.J., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on Artificial Intelligence (“AI”)-driven therapeutic drug development for the treatment of non-alcoholic steatohepatitis (“NASH”) and hepatocellular c
